Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPiD
PACTR202302536807007Phase 4Recruiting
- Sponsor
- Duke Clinical Research Institute
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of artemether + lumefantrine in malaria (2 arms), sponsored by Duke Clinical Research Institute. Primary endpoints: Composite adverse birth and neonatal outcome, Low birth weight and 6 more. Started Apr 2023; status: recruiting.
02
Drugs
artemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202302536807007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302536807007.